Capricor Therapeutics Inc (CAPR, Financial)(30-Year Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2019. Capricor Therapeutics Inc is a clinical stage biotechnology company developing products for the treatment of cardiovascular diseases with a focus on heart failure. Capricor Therapeutics Inc has a market cap of $6.743 million; its shares were traded at around $1.29 with and P/S ratio of 2.97. GuruFocus has detected 3 severe warning signs with Capricor Therapeutics Inc. .
For the last quarter Capricor Therapeutics Inc reported a revenue of $0.22 million, compared with the revenue of $0.65 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $1.01 million, a decrease of 39.9% from the previous year. For the complete 30-year financial data, please go here.. For the last five years Capricor Therapeutics Inc had an average revenue decline of 28.6% a year.
The reported loss per diluted share was $2.06 for the year, an increase of -60.4% from previous year. The Capricor Therapeutics Inc had an operating margin of -769.55%, compared with the operating margin of -917.24% a year before. The 10-year historical median operating margin of Capricor Therapeutics Inc is -393.04%. The profitability rank of the company is 2 (out of 10).
For the complete 20-year historical financial data of CAPR, click here.
